- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. stock price live, this page displays NASDAQ CMPX stock exchange data. View the CMPX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Compass Therapeutics, Inc. real time stock price chart below.
What Is the Compass Therapeutics, Inc. Stock Price Today?
The Compass Therapeutics, Inc. stock price today is 2.260.
What Is the Stock Symbol for Compass Therapeutics, Inc.?
The stock symbol for Compass Therapeutics, Inc. is "CMPX."
What Stock Exchange Does Compass Therapeutics, Inc. Trade On?
Compass Therapeutics, Inc. is listed and trades on the NASDAQ stock exchange.
Is Compass Therapeutics, Inc. a Good Stock to Buy?
Determining whether Compass Therapeutics, Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMPX quote. (ISIN: US20454B1044)
What Is the Compass Therapeutics, Inc. Stock Price Today?
The Compass Therapeutics, Inc. stock price today is 2.260.
What Is the Stock Symbol for Compass Therapeutics, Inc.?
The stock symbol for Compass Therapeutics, Inc. is "CMPX."
What Stock Exchange Does Compass Therapeutics, Inc. Trade On?
Compass Therapeutics, Inc. is listed and trades on the NASDAQ stock exchange.
Is Compass Therapeutics, Inc. a Good Stock to Buy?
Determining whether Compass Therapeutics, Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMPX quote. (ISIN: US20454B1044)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.230
2.370
52 wk Range
1.610
6.880
CMPX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.2302.370
52 wk Range
1.6106.880
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CMPX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.917
Upside
+294.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings downwards for the upcoming period
Form 8K Compass Therapeutics, Inc. For: 6 August- Investing.com
Form DEF 14A Compass Therapeutics, Inc. For: 3 June- Investing.com
- Form 8K Compass Therapeutics, Inc. For: 6 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.917
(+294.54% Upside)
Compass Therapeutics, Inc. Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.14 missed forecast of -$0.12; stock fell 2.88% in premarket trading to $2.7
- Strong cash position of $101M extends runway into 2027; YTD stock gains of 86% and 147% return over past year
- Ongoing trials for Tivesamig and CTX-8,371 show promise; potential BLA submission for Tivesamig in 2026
- Cautious guidance with projected EPS losses; IND filing for CTX-10,726 anticipated in Q4 2025
- Analyst price targets range from $6 to $32; stock slightly undervalued per InvestingPro Fair Value analysis
Last Updated: 2025-08-11, 09:10 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.13 / -0.11
Revenue / Forecast
-- / -654.55B
Compare CMPX to Peers and Sector
Metrics to compare | CMPX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMPXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | −1.7x | −0.4x | |
PEG Ratio | −0.54 | −0.77 | 0.00 | |
Price/Book | 2.5x | 3.8x | 2.6x | |
Price / LTM Sales | - | 27.5x | 3.1x | |
Upside (Analyst Target) | 209.7% | 68.4% | 48.4% | |
Fair Value Upside | Unlock | 22.7% | 6.5% | Unlock |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Compass Therapeutics, (CMPX) Stock Price Today?
The Compass Therapeutics, stock price today is 2.260 USD.
What Stock Exchange Does Compass Therapeutics, Trade On?
Compass Therapeutics, is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Compass Therapeutics,?
The stock symbol for Compass Therapeutics, is "CMPX."
What Is the Compass Therapeutics, Market Cap?
As of today, Compass Therapeutics, market cap is 407.000M USD.
What Is Compass Therapeutics,'s Earnings Per Share (TTM)?
The Compass Therapeutics, EPS (TTM) is -0.404.
When Is the Next Compass Therapeutics, Earnings Date?
Compass Therapeutics, will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is CMPX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Compass Therapeutics, Stock Split?
Compass Therapeutics, has split 0 times.
How Many Employees Does Compass Therapeutics, Have?
Compass Therapeutics, has 39 employees.
What is the current trading status of Compass Therapeutics, (CMPX)?
As of Aug 14, 2026, Compass Therapeutics, (CMPX) is trading at a price of 2.260 USD, with a previous close of 2.260 USD. The stock has fluctuated within a day range of 2.230 USD to 2.370 USD, while its 52-week range spans from 1.610 USD to 6.880 USD.
What Is Compass Therapeutics, (CMPX) Price Target According to Analysts?
The average 12-month price target for Compass Therapeutics, is 8.917 USD, with a high estimate of 24 USD and a low estimate of 5 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +294.54% Upside potential.
What Is the CMPX Premarket Price?
CMPX's last pre-market stock price is 2.251 USD. The pre-market share volume is 170.000, and the stock has decreased by -0.009, or -0.400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.